Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Budoprutug (CD19 Antibody) in Immune Thrombocytopenia. The expected timing is based on the latest available company guidance and may change.
05/05/26:- Initial Phase 1b/2a low-dose B-cell and platelet data expected June 2026. Higher-dose cohort data expected by year-end 2026. 05/14/26:- EHA 2026 poster will present low-dose cohort data June 13, 2026. 06/11/26:- Ph1b/2a NCT07043946 initial ITP data reported; additional high-dose cohort data expected Year-End 2026. 08/06/26:- ITP 500 mg and 1000 mg cohort data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.